BDP5290

Hersteller MedChem Express
Kategorie
Typ Inhibitors
Specific against other
Menge 2mg
ArtNr HY-12437-2mg
Eclass 6.1 30220300
Eclass 9.0 32160605
Lieferbar
CAS
1817698-21-7
MWt
371.8241
Formula
C17H18ClN7O
Solubility
DMSO: 12.5 mg/mL (Need ultrasonic)
Clinical_Information
No Development Reported
Pathway
TGF-beta/Smad, Stem Cell/Wnt, Cell Cycle/DNA Damage
Target
ROCK, ROCK, ROCK
Biological Activity
BDP5290 is a potent inhibitor of both ROCK and MRCK with IC50s of 5 nM, 50 nM, 10 nM and 100 nM for ROCK1, ROCK2, MRCK1 and MRCK2, respectively.
IC50 & Target: IC50: 5 nM (ROCK1), 50 nM (ROCK2), 10 nM (MRCK1), 100 nM (MRCK2)[1]
In Vitro: The Ki of BDP5290 for MRCKalpha is 10 nM, which is slightly more than the Ki of 4 nM for MRCKbeta. 3 uM BDP5290 completely inhibits myosin II light chain (MLC) phosphorylation induced by MRCKbeta, but not by ROCK1 or ROCK2. At higher concentrations, BDP5290 reduces MLC phosphorylation (pMLC) to undetectable levels. BDP5290 reduces MDA-MB-231 invasion at all tested concentrations starting from 0.1 uM, with virtually complete inhibition at 10 uM. After 24 hours in the presence of BDP5290 cell viability is slightly reduced with an EC50 ?>10 uM. Wound closure is inhibited by?>60% at 1 uM BDP5290, a concentration that has no effect on cell viability[2].
Menge: 2mg
Lieferbar: In stock
Listenpreis: 178,57 €
Rabatt: -10,0%
Preis: 160,71 €
Sie sparen: 17,86 €
lieferbar

Angebot anfordern

Fragen zum Produkt?

Ihr Ansprechpartner:

Arne Pelz

sales@hoelzel.de

 
Schließen